Addressing cholera with an 'integrated approach' in 2013

Published on January 16, 2013 at 7:00 AM · No Comments

"There has been so much news related to cholera and cholera research since the start of 2013 I can only hope it means this year will be a banner year for prevention efforts," Helen Matzger, a program officer in new vaccine delivery at the Bill & Melinda Gates Foundation, writes in the foundation's "Impatient Optimists" blog. She summarizes several recent articles covering cholera and asks, "How do we as a concerned community about this disease come together to work on an integrated approach to cholera control ... ? Where are the billions of dollars in funding? Perhaps most importantly, how does the cholera community work to increase the international and national level political will to work on a disease that almost solely affects the poorest of the poor?" Matzger continues, "These are hard questions and ones that I think about often. There are, however, hopeful signs that cholera is something a lot of other people are thinking more often about too. And we can all hope this collective thinking will lead to true action that benefits those at risk for cholera." She summarizes several initiatives working to fight cholera (1/14).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Posted in: Disease/Infection News | Healthcare News

Tags: , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Imaxio, DKFZ partner to evaluate potential of IMX313 with candidate vaccine targeting HPV